Molecularly targeted drugsのメーカーや取扱い企業、製品情報、参考価格、ランキングをまとめています。
イプロスは、 製造業 ・ BtoB における情報を集めた国内最大級の技術データベースサイトです。

Molecularly targeted drugs - メーカー・企業と業務用製品 | イプロスものづくり

Molecularly targeted drugsの製品一覧

1～5 件を表示 ／ 全 5 件

表示件数
Aptamer drug discovery technology "RiboART System"

Aptamer drug discovery technology "RiboART System"

We can develop various new drugs that are not limited to specific diseases or target proteins.

Our core drug discovery technology, the "RiboART (Ribomic Aptamer Refined Therapeutics) System," is built on comprehensive technologies, knowledge, and experience related to aptamer drug discovery, establishing a platform (drug discovery foundation) that can be universally applied to the creation of new drug candidates. By using the "RiboART System," it is possible to develop various new drugs that are not limited to specific diseases or target proteins. Please feel free to contact us if you have any inquiries. 【Features of Aptamer Pharmaceuticals】 ■ Strong target binding ability ■ Few restrictions on targets ■ Easy chemical modifications ■ Production through chemical synthesis ■ Low antigenicity *For more details, please download the PDF or contact us.

  • Other contract manufacturing
  • Technology Development
  • Molecularly targeted drugs

ブックマークに追加いたしました

ブックマーク一覧

ブックマークを削除いたしました

ブックマーク一覧

これ以上ブックマークできません

会員登録すると、ブックマークできる件数が増えて、ラベルをつけて整理することもできます

無料会員登録
Exudative Age-related Macular Degeneration Clinical Trial

Exudative Age-related Macular Degeneration Clinical Trial

RBM-007 is considered a potential new treatment for wet AMD patients with no prior treatment history!

We would like to introduce the clinical trials conducted by our company. As a clinical trial targeting exudative age-related macular degeneration (wet AMD), a Phase 2 clinical trial was conducted in the United States after the implementation of a Phase 1/2a clinical trial, aimed at confirming the clinical proof of concept (POC) of multiple administrations of RBM-007. Furthermore, a physician-led clinical trial was conducted in the United States to evaluate the efficacy and safety of RBM-007 monotherapy in treatment-naive wet AMD patients. 【Main Trials】 ■ Randomized double-blind trial ■ Open-label trial ■ Physician-led clinical trial *For more details, please refer to the PDF materials or feel free to contact us.

  • Other Testing Contract
  • Molecularly targeted drugs

ブックマークに追加いたしました

ブックマーク一覧

ブックマークを削除いたしました

ブックマーク一覧

これ以上ブックマークできません

会員登録すると、ブックマークできる件数が増えて、ラベルをつけて整理することもできます

無料会員登録
Clinical Trial: Achondroplasia

Clinical Trial: Achondroplasia

RBM-007 strongly suggests that it could be a new drug for cartilage dysplasia!

We would like to introduce the clinical trials conducted by our company. The project concerning achondroplasia received support from the Japan Agency for Medical Research and Development (AMED) and began a Phase 1 trial in July 2020 at a domestic clinical trial facility to investigate the safety, tolerability, and pharmacokinetics of RBM-007, which was conducted until May 2021. Regarding the Phase 2 trial of this project, it has been adopted as a pre-commercialization support project for orphan drugs by AMED for three years starting from the fiscal year 2021. [Main Trials] ■ Phase 1 Clinical Trial ■ Early Phase 2 Observational Trial ■ Early Phase 2 Clinical Trial ■ Early Phase 2 Long-term Clinical Trial *For more details, please refer to the PDF materials or feel free to contact us.

  • Other Testing Contract
  • Molecularly targeted drugs

ブックマークに追加いたしました

ブックマーク一覧

ブックマークを削除いたしました

ブックマーク一覧

これ以上ブックマークできません

会員登録すると、ブックマークできる件数が増えて、ラベルをつけて整理することもできます

無料会員登録
Aptamer drug discovery technology

Aptamer drug discovery technology

Created using the SELEX method (in vitro artificial evolution method)! It is possible to develop various new drugs.

We would like to introduce our "Aptamer Drug Discovery Technology." Our core drug discovery technology, the "RiboART System," is built on comprehensive technologies, knowledge, and experience related to aptamer drug discovery, creating a platform (drug discovery foundation) that can be widely applied to the generation of new drug candidates. By using this system, it is possible to create various new drugs that are not limited to specific diseases or target proteins. 【Flow】 ■ SELEX method ■ Binding property measurement ■ Shortening, re-SELEX, chemical modification ■ Cell testing ■ Animal testing ■ Toxicity testing *For more details, please refer to the PDF document or feel free to contact us.

  • Other Protein Research
  • Molecularly targeted drugs

ブックマークに追加いたしました

ブックマーク一覧

ブックマークを削除いたしました

ブックマーク一覧

これ以上ブックマークできません

会員登録すると、ブックマークできる件数が増えて、ラベルをつけて整理することもできます

無料会員登録
[Research Material] Global Market for C-MET and HGF Inhibitors

[Research Material] Global Market for C-MET and HGF Inhibitors

Global Market for C-MET and HGF Inhibitors: Cabozantinib, Crizotinib, Others, Hospitals, Drugstores

This research report (Global C-MET & HGF Inhibitors Market) investigates and analyzes the current status and outlook for the global market of C-MET & HGF inhibitors over the next five years. It includes information on the overview of the global C-MET & HGF inhibitors market, trends of major companies (sales, selling prices, market share), market size by segment, market size by major regions, and distribution channel analysis. The market segments by type include cabozantinib, crizotinib, and others, while the segments by application focus on hospitals and drugstores. The regional segments are categorized into North America, the United States, Europe, Asia-Pacific, Japan, China, India, South Korea, Southeast Asia, South America, the Middle East, and Africa to calculate the market size of C-MET & HGF inhibitors. It also includes the market share of major companies in C-MET & HGF inhibitors, product and business overviews, and sales performance.

  • Other services
  • Molecularly targeted drugs

ブックマークに追加いたしました

ブックマーク一覧

ブックマークを削除いたしました

ブックマーク一覧

これ以上ブックマークできません

会員登録すると、ブックマークできる件数が増えて、ラベルをつけて整理することもできます

無料会員登録
COPYRIGHT © 2001-2026 IPROS CORPORATION ALL RIGHTS RESERVED.